{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:17:21Z","timestamp":1782361041970,"version":"3.54.5"},"reference-count":130,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>The onset of decompensation in advanced chronic liver disease (ACLD) is a hallmark in natural history, with a poor prognosis and a significantly increased liver-related mortality. Etiological treatments for viral hepatitis or abstinence in cirrhosis due to alcohol abuse have demonstrated that some patients experience partial to complete clinical and analytical improvement, a stage termed \u201crecompensation.\u201d Although recompensation is primarily defined clinically based on treatable etiologies, it is still evolving for conditions like metabolic dysfunction-associated steatotic liver disease (MASLD). Despite the need for specific biomarkers in hepatic recompensation, no biomarkers have been thoroughly studied in this context. Biomarkers identified in compensated ACLD (cACLD) following etiological treatment might be explored for recompensation. Although the pathophysiology mechanisms underlying the hepatic recompensation remain unclear, understanding the mechanism involved in cirrhosis decompensation could help identify potential targets for recompensation. This review provides an update on the hepatic recompensation concept, examines the existing data on invasive and non-invasive biomarkers, mainly in cACLD after cure, that could be raised in recompensation, and explores future therapeutic targets for the hepatic recompensation process.<\/jats:p>","DOI":"10.1055\/a-2542-9930","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T23:34:55Z","timestamp":1743723295000},"page":"129-143","source":"Crossref","is-referenced-by-count":1,"title":["Recompensation in Cirrhosis: Biomarkers and Strategies"],"prefix":"10.1055","volume":"45","author":[{"given":"Wagner","family":"Ram\u00edrez-Quesada","sequence":"additional","affiliation":[{"name":"Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Cl\u00ednic, Institut de Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Departament de Medicina i Ci\u00e8ncies de la Salut, Fundaci\u00f3 de Recerca Cl\u00ednic Barcelona (FRCB-IDIBAPS), Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver), Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edilmar","family":"Alvarado-Tapias","sequence":"additional","affiliation":[{"name":"Centre for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Gastroenterology and Hepatology Department, Hospital Santa Creu i Sant Pau, Autonomus University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Shalaby","sequence":"additional","affiliation":[{"name":"Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Cl\u00ednic, Institut de Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Departament de Medicina i Ci\u00e8ncies de la Salut, Fundaci\u00f3 de Recerca Cl\u00ednic Barcelona (FRCB-IDIBAPS), Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver), Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Hern\u00e1ndez-Gea","sequence":"additional","affiliation":[{"name":"Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Cl\u00ednic, Institut de Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Departament de Medicina i Ci\u00e8ncies de la Salut, Fundaci\u00f3 de Recerca Cl\u00ednic Barcelona (FRCB-IDIBAPS), Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver), Universitat de Barcelona, Barcelona, Spain"},{"name":"Centre for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12072-018-9850-5","article-title":"Liver cirrhosis and cancer: comparison of mortality","volume":"12","author":"W Chung","year":"2018","journal-title":"Hepatol Int"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/tri.13008","article-title":"Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study","volume":"30","author":"A D Aravinthan","year":"2017","journal-title":"Transpl Int"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2021.02.033","article-title":"A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement","volume":"75","author":"E Pose","year":"2021","journal-title":"J Hepatol"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1111\/liv.15676","article-title":"Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis","volume":"43","author":"B S Hofer","year":"2023","journal-title":"Liver Int"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1111\/liv.15690","article-title":"Defining recompensation of alcohol-related liver disease: a step beyond decompensated cirrhosis","volume":"43","author":"J Gratac\u00f3s-Gin\u00e8s","year":"2023","journal-title":"Liver Int"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/jhep.2001.26512","article-title":"Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort","volume":"34","author":"F Y Yao","year":"2001","journal-title":"Hepatology"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jhep.2022.07.037","article-title":"Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis","volume":"77","author":"Q Wang","year":"2022","journal-title":"J Hepatol"},{"issue":"09","key":"ref8","first-page":"100814","article-title":"Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis","volume":"5","author":"V WK Hui","year":"2023","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"07","key":"ref9","doi-asserted-by":"crossref","first-page":"101091","DOI":"10.1016\/j.jhepr.2024.101091","article-title":"Durability and on-treatment predictors of recompensation in entecavir-treated patients with hepatitis B and decompensated cirrhosis","volume":"6","author":"Y Deng","year":"2024","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1111\/liv.13878","article-title":"Delisting HCV-infected liver transplant candidates who improved after viral eradication: outcome 2 years after delisting","volume":"38","author":"G Perricone","year":"2018","journal-title":"Liver Int"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.cgh.2020.09.033","article-title":"In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent","volume":"19","author":"T Bittermann","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"06","key":"ref12","doi-asserted-by":"crossref","first-page":"101714","DOI":"10.1016\/j.clinre.2021.101714","article-title":"Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: a long-term single-center experience","volume":"45","author":"E A Nabatchikova","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"e043083","DOI":"10.1136\/bmjopen-2020-043083","article-title":"Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study","volume":"11","author":"X Xu","year":"2021","journal-title":"BMJ Open"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII\u2014renewing consensus in portal hypertension","volume":"76","author":"R de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"S 01","key":"ref15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jvh.12875","article-title":"Hepatitis C: the beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe","volume":"25","author":"G V Papatheodoridis","year":"2018","journal-title":"J Viral Hepat"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"M Mandorfer","year":"2016","journal-title":"J Hepatol"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis","volume":"153","author":"S Lens","year":"2017","journal-title":"Gastroenterology"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"P Nahon","year":"2017","journal-title":"Gastroenterology"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.gastro.2016.03.036","article-title":"Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension","volume":"151","author":"V Di Marco","year":"2016","journal-title":"Gastroenterology"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3851\/IMP3186","article-title":"Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis","volume":"23","author":"M Persico","year":"2018","journal-title":"Antivir Ther"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cgh.2019.07.047","article-title":"Long-term benefits of sustained virologic response for patient-reported outcomes in patients with chronic hepatitis C virus infection","volume":"18","author":"Z M Younossi","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"14","key":"ref22","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.3390\/cancers13143455","article-title":"Characteristics and survival outcomes of hepatocellular carcinoma developed after HCV SVR","volume":"13","author":"M L Yeh","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"ref23","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ncpgasthep0961","article-title":"Mechanisms of disease: HCV-induced liver injury","volume":"4","author":"J A Mengshol","year":"2007","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"08","key":"ref24","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1053\/j.gastro.2018.03.022","article-title":"Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection","volume":"154","author":"O El-Sherif","year":"2018","journal-title":"Gastroenterology"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"74","author":"L AP Krassenburg","year":"2021","journal-title":"J Hepatol"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: real-world experience from HCV-TARGET cohort","volume":"73","author":"E C Verna","year":"2020","journal-title":"J Hepatol"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jhep.2017.08.008","article-title":"Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation","volume":"67","author":"J M Pascasio","year":"2017","journal-title":"J Hepatol"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","volume":"65","author":"L S Belli","year":"2016","journal-title":"J Hepatol"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"M F Yuen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"9865","key":"ref30","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"P Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"100847","DOI":"10.1016\/j.jhepr.2023.100847","article-title":"Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"5","author":"Y S Lim","year":"2023","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1007\/s12072-023-10579-w","article-title":"Recompensation in treatment-na\u00efve HBV-related decompensated cirrhosis: a 5-year multi-center observational study comparing patients with ascites and bleeding","volume":"17","author":"Z He","year":"2023","journal-title":"Hepatol Int"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-018-0014-7","article-title":"Alcoholic liver disease","volume":"4","author":"H K Seitz","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0168-8278(86)80006-X","article-title":"Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage","volume":"2","author":"A Par\u00e9s","year":"1986","journal-title":"J Hepatol"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"F Tacke","year":"2024","journal-title":"J Hepatol"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"C Estes","year":"2018","journal-title":"Hepatology"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41575-023-00846-4","article-title":"Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease","volume":"21","author":"G Feng","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.3390\/nu9101052","article-title":"Mediterranean diet and multi-ingredient-based interventions for the management of non-alcoholic fatty liver disease","volume":"9","author":"M Su\u00e1rez","year":"2017","journal-title":"Nutrients"},{"issue":"03","key":"ref39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0041-1723751","article-title":"Effects of mediterranean diet in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials","volume":"41","author":"T Kawaguchi","year":"2021","journal-title":"Semin Liver Dis"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74\u2009mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"R Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"S A Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cgh.2020.04.068","article-title":"Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis","volume":"19","author":"F Bazerbachi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"17","key":"ref43","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.3390\/jcm10173783","article-title":"Effects of Roux-en-Y gastric bypass and sleeve gastrectomy on non-alcoholic fatty liver disease: a 12-month follow-up study with paired liver biopsies","volume":"10","author":"J S Pedersen","year":"2021","journal-title":"J Clin Med"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jhep.2024.05.033","article-title":"Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD","volume":"81","author":"R Paternostro","year":"2024","journal-title":"J Hepatol"},{"issue":"05","key":"ref45","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"M E Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"05","key":"ref46","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep.32204","article-title":"Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis","volume":"75","author":"A J Sanyal","year":"2022","journal-title":"Hepatology"},{"issue":"01","key":"ref47","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1186\/s13063-021-05695-7","article-title":"Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): study protocol for a randomized controlled trial (TESLA-NASH study)","volume":"22","author":"L Lav\u00edn-Alconero","year":"2021","journal-title":"Trials"},{"issue":"07","key":"ref48","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16023","article-title":"Review article: pathophysiology and management of primary biliary cholangitis","volume":"52","author":"K K Leung","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"07","key":"ref49","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"F Nevens","year":"2016","journal-title":"N Engl J Med"},{"issue":"23","key":"ref50","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"C Corpechot","year":"2018","journal-title":"N Engl J Med"},{"issue":"09","key":"ref51","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"G M Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"issue":"09","key":"ref52","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"K V Kowdley","year":"2024","journal-title":"N Engl J Med"},{"issue":"08","key":"ref53","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2023.02.005","article-title":"New treatment paradigms in primary biliary cholangitis","volume":"21","author":"C Levy","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"08","key":"ref54","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/apt.17908","article-title":"Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis","volume":"59","author":"B S Hofer","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"ref55","volume-title":"Response biomarker","author":"FDA-NIH Biomarker Working Group","year":"2021"},{"issue":"06","key":"ref56","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJM200102083440604","article-title":"Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct","volume":"344","author":"P Hammel","year":"2001","journal-title":"N Engl J Med"},{"issue":"05","key":"ref57","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1053\/gast.2002.33367","article-title":"Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C","volume":"122","author":"M J Arthur","year":"2002","journal-title":"Gastroenterology"},{"issue":"05","key":"ref58","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jfma.2020.11.018","article-title":"Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers","volume":"120","author":"C H Cheng","year":"2021","journal-title":"J Formos Med Assoc"},{"issue":"06","key":"ref59","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0168-8278(01)00218-5","article-title":"Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B","volume":"35","author":"Y O Kweon","year":"2001","journal-title":"J Hepatol"},{"issue":"06","key":"ref60","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/hep.20251","article-title":"Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss","volume":"39","author":"J B Dixon","year":"2004","journal-title":"Hepatology"},{"issue":"04","key":"ref61","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2004.01.009","article-title":"Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis","volume":"40","author":"A J Czaja","year":"2004","journal-title":"J Hepatol"},{"issue":"04","key":"ref62","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"G Lassailly","year":"2020","journal-title":"Gastroenterology"},{"issue":"06","key":"ref63","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jhep.2024.06.028","article-title":"Metabolic phenotyping of patients with advanced chronic liver disease for better characterization of cirrhosis regression","volume":"81","author":"Y P Mendoza","year":"2024","journal-title":"J Hepatol"},{"issue":"11","key":"ref64","first-page":"1599","article-title":"Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis","volume":"124","author":"I R Wanless","year":"2000","journal-title":"Arch Pathol Lab Med"},{"issue":"03","key":"ref65","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"R de Franchis","year":"2015","journal-title":"J Hepatol"},{"issue":"10","key":"ref66","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrgastro.2009.149","article-title":"The clinical use of HVPG measurements in chronic liver disease","volume":"6","author":"J Bosch","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"160","key":"ref67","first-page":"e58819","article-title":"Measurement of the hepatic venous pressure gradient and transjugular liver biopsy","author":"T Reiberger","year":"2020","journal-title":"J Vis Exp"},{"issue":"06","key":"ref68","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","article-title":"Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension","volume":"73","author":"S Lens","year":"2020","journal-title":"J Hepatol"},{"issue":"03","key":"ref69","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.30885","article-title":"Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy","volume":"71","author":"M Mandorfer","year":"2020","journal-title":"Hepatology"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jhep.2024.03.015","article-title":"Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure","volume":"81","author":"G Semmler","year":"2024","journal-title":"J Hepatol"},{"issue":"03","key":"ref71","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/gast.1996.v111.pm8780575","article-title":"Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study","volume":"111","author":"J Vorobioff","year":"1996","journal-title":"Gastroenterology"},{"issue":"09","key":"ref72","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.cgh.2022.11.033","article-title":"Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis","volume":"21","author":"B S Hofer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"ref73","doi-asserted-by":"crossref","first-page":"101170","DOI":"10.1016\/j.jhepr.2024.101170","article-title":"Persistent varices in cured patients: understanding the role of hepatic venous pressure gradient","volume":"6","author":"P Olivas","year":"2024","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"07","key":"ref74","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1053\/j.gastro.2024.08.018","article-title":"Recompensation of chronic hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: prospective cohort study from an HCV elimination program","volume":"167","author":"M Premkumar","year":"2024","journal-title":"Gastroenterology"},{"issue":"08","key":"ref75","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/00365521.2023.2181037","article-title":"Development and validation of a nomogram to predict recompensation in HBV-related cirrhosis with ascites as the single first decompensating event","volume":"58","author":"S Wen","year":"2023","journal-title":"Scand J Gastroenterol"},{"issue":"01","key":"ref76","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.gastro.2012.10.001","article-title":"Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis","volume":"144","author":"A Berzigotti","year":"2013","journal-title":"Gastroenterology"},{"issue":"06","key":"ref77","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jhep.2022.08.025","article-title":"Non-invasive tests for clinically significant portal hypertension after HCV cure","volume":"77","author":"G Semmler","year":"2022","journal-title":"J Hepatol"},{"issue":"06","key":"ref78","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/10815589231171403","article-title":"Spleen size change after hepatitis C treatment: a simple parameter to predict clinical outcomes","volume":"71","author":"S Prakash","year":"2023","journal-title":"J Investig Med"},{"issue":"06","key":"ref79","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1042\/CS20171370","article-title":"Extrahepatic angiogenesis hinders recovery of portal hypertension and collaterals in rats with cirrhosis resolution","volume":"132","author":"S J Hsu","year":"2018","journal-title":"Clin Sci (Lond)"},{"issue":"04","key":"ref80","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/hep4.1157","article-title":"Influence of spontaneous splenorenal shunts on clinical outcomes in decompensated cirrhosis and after liver transplantation","volume":"2","author":"K Saks","year":"2018","journal-title":"Hepatol Commun"},{"issue":"01","key":"ref81","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1432-2277.1992.tb01715.x","article-title":"The role of spontaneous portosystemic shunts in the course of orthotopic liver transplantation","volume":"5","author":"L De Carlis","year":"1992","journal-title":"Transpl Int"},{"issue":"05","key":"ref82","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP1807","article-title":"The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon\/ribavirin therapy","volume":"16","author":"R D'Ambrosio","year":"2011","journal-title":"Antivir Ther"},{"issue":"01","key":"ref83","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1002\/deo2.11","article-title":"Changes of esophageal varices in hepatitis C patients after achievement of a sustained viral response by direct-acting antivirals","volume":"2","author":"S Takakusagi","year":"2021","journal-title":"DEN Open"},{"issue":"02","key":"ref84","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00535-019-01619-0","article-title":"Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients","volume":"55","author":"M Puigveh\u00ed","year":"2020","journal-title":"J Gastroenterol"},{"issue":"02","key":"ref85","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2021.09.013","article-title":"Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR","volume":"76","author":"R D'Ambrosio","year":"2022","journal-title":"J Hepatol"},{"issue":"03","key":"ref86","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jhep.2011.07.005","article-title":"Non invasive evaluation of portal hypertension using transient elastography","volume":"56","author":"L Castera","year":"2012","journal-title":"J Hepatol"},{"issue":"11","key":"ref87","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.14309\/ajg.0000000000001887","article-title":"A combined Baveno VII and spleen stiffness algorithm to improve the noninvasive diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease","volume":"117","author":"E Dajti","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"09","key":"ref88","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2468-1253(23)00150-4","article-title":"Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis","volume":"8","author":"E Dajti","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"02","key":"ref89","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/HEP.0000000000001005","article-title":"Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure","volume":"81","author":"G Semmler","year":"2025","journal-title":"Hepatology"},{"issue":"05","key":"ref90","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/hep.21665","article-title":"Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis","volume":"45","author":"F Vizzutti","year":"2007","journal-title":"Hepatology"},{"issue":"02","key":"ref91","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhep.2024.03.035","article-title":"Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases","volume":"81","author":"M Thiele","year":"2024","journal-title":"J Hepatol"},{"issue":"09","key":"ref92","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1055\/s-0043-112656","article-title":"Interferon-free cure of chronic hepatitis C is associated with weight gain during long-term follow-up","volume":"55","author":"B Schlevogt","year":"2017","journal-title":"Z Gastroenterol"},{"issue":"10","key":"ref93","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3390\/biomedicines9101495","article-title":"Weight gain after interferon-free treatment of chronic hepatitis C\u2014results from the German hepatitis C-registry (DHC-R)","volume":"9","author":"B Schlevogt","year":"2021","journal-title":"Biomedicines"},{"issue":"07","key":"ref94","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s11606-020-05782-6","article-title":"Excess weight gain after cure of hepatitis C infection with direct-acting antivirals","volume":"35","author":"A Do","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"01","key":"ref95","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jhep.2014.08.003","article-title":"Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases","volume":"61","author":"F Negro","year":"2014","journal-title":"J Hepatol"},{"issue":"09","key":"ref96","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/lt.25485","article-title":"Superior wait-list outcomes in patients with alcohol-associated liver disease compared with other indications for liver transplantation","volume":"25","author":"J M Giard","year":"2019","journal-title":"Liver Transpl"},{"issue":"09","key":"ref97","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1007\/s11695-019-04030-z","article-title":"Adipose tissue composition in obesity and after bariatric surgery","volume":"29","author":"G F Adami","year":"2019","journal-title":"Obes Surg"},{"issue":"08","key":"ref98","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1210\/en.2011-2145","article-title":"The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control","volume":"153","author":"D J Pournaras","year":"2012","journal-title":"Endocrinology"},{"issue":"02","key":"ref99","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tem.2024.05.009","article-title":"Recompensation in MASLD-related cirrhosis via metabolic bariatric surgery","volume":"36","author":"G Feng","year":"2025","journal-title":"Trends Endocrinol Metab"},{"issue":"01","key":"ref100","first-page":"839275","article-title":"Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?","volume":"2013","author":"S Hafeez","year":"2013","journal-title":"J Obes"},{"issue":"04","key":"ref101","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jhep.2020.10.004","article-title":"Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality","volume":"74","author":"D Costa","year":"2021","journal-title":"J Hepatol"},{"issue":"02","key":"ref102","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"P Angeli","year":"2018","journal-title":"J Hepatol"},{"issue":"38","key":"ref103","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.3748\/wjg.v29.i38.5383","article-title":"Impressive recompensation in transjugular intrahepatic portosystemic shunt-treated individuals with complications of decompensated cirrhosis based on Baveno VII criteria","volume":"29","author":"L Gao","year":"2023","journal-title":"World J Gastroenterol"},{"issue":"11","key":"ref104","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1111\/liv.16095","article-title":"Recompensation after TIPS reduces the incidence of hepatocellular carcinoma and increases survival in patients with cirrhosis","volume":"44","author":"J S\u00e1nchez","year":"2024","journal-title":"Liver Int"},{"issue":"05","key":"ref105","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","article-title":"Cirrhosis as new indication for statins","volume":"69","author":"J Bosch","year":"2020","journal-title":"Gut"},{"issue":"06","key":"ref106","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2007.01.020","article-title":"Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats","volume":"46","author":"J G Abraldes","year":"2007","journal-title":"J Hepatol"},{"issue":"05","key":"ref107","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"J G Abraldes","year":"2009","journal-title":"Gastroenterology"},{"issue":"03","key":"ref108","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","article-title":"Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis","volume":"126","author":"C Zafra","year":"2004","journal-title":"Gastroenterology"},{"issue":"01","key":"ref109","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase","volume":"46","author":"J Trebicka","year":"2007","journal-title":"Hepatology"},{"issue":"05","key":"ref110","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","article-title":"Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease","volume":"74","author":"Z Boyer-Diaz","year":"2021","journal-title":"J Hepatol"},{"issue":"12","key":"ref111","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"P N Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"L B Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"ref113","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1177\/2050640620944140","article-title":"Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats","volume":"8","author":"K Brusilovskaya","year":"2020","journal-title":"United European Gastroenterol J"},{"issue":"01","key":"ref114","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000088545","article-title":"Platelet aggregation in portal hypertension and its modification by ultra-low doses of aspirin","volume":"34","author":"F X Eizayaga","year":"2005","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"04","key":"ref115","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction","volume":"66","author":"P Schwabl","year":"2017","journal-title":"J Hepatol"},{"issue":"01","key":"ref116","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(14)60017-9","article-title":"O15 Effects of the FXR agonist obeticholic acid on hepatic venous pressure gradient (HVPG) in alcoholic cirrhosis: a proof of concept phase 2a study","volume":"60","author":"R Mookerjee","year":"2014","journal-title":"J Hepatol"},{"issue":"06","key":"ref117","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/hep.29084","article-title":"The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells","volume":"65","author":"M Vilaseca","year":"2017","journal-title":"Hepatology"},{"issue":"01","key":"ref118","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0168-8278(23)00442-7","article-title":"Rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebo-controlled trial","volume":"78","author":"A P Sanchez","year":"2023","journal-title":"J Hepatol"},{"issue":"05","key":"ref119","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"E Villa","year":"2012","journal-title":"Gastroenterology"},{"issue":"06","key":"ref120","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"F Tacke","year":"2017","journal-title":"J Hepatol"},{"issue":"01","key":"ref121","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study","volume":"22","author":"Q M Anstee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"03","key":"ref122","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"V Ratziu","year":"2020","journal-title":"Hepatology"},{"issue":"01","key":"ref123","doi-asserted-by":"crossref","first-page":"4949148","DOI":"10.1155\/2022\/4949148","article-title":"TAK-242 ameliorates hepatic fibrosis by regulating the liver-gut axis","volume":"2022","author":"S Liu","year":"2022","journal-title":"BioMed Res Int"},{"issue":"04","key":"ref124","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3390\/jcm9041140","article-title":"The medium-chain fatty acid receptor GPR84 mediates myeloid cell infiltration promoting steatohepatitis and fibrosis","volume":"9","author":"T Puengel","year":"2020","journal-title":"J Clin Med"},{"issue":"16","key":"ref125","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2174\/156802605775009720","article-title":"Caspase inhibitors: a pharmaceutical industry perspective","volume":"5","author":"S D Linton","year":"2005","journal-title":"Curr Top Med Chem"},{"issue":"08","key":"ref126","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41574-021-00507-z","article-title":"Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus","volume":"17","author":"D Ferguson","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"26","key":"ref127","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMra2207599","article-title":"Alcohol-associated hepatitis","volume":"387","author":"R Bataller","year":"2022","journal-title":"N Engl J Med"},{"issue":"05","key":"ref128","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2009.06.024","article-title":"Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats","volume":"51","author":"T Reiberger","year":"2009","journal-title":"J Hepatol"},{"issue":"01","key":"ref129","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2036.2011.04896.x","article-title":"The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma\u2014a pilot study","volume":"35","author":"M Pinter","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"05","key":"ref130","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1053\/j.gastro.2014.01.061","article-title":"Vascular endothelial growth factor promotes fibrosis resolution and repair in mice","volume":"146","author":"L Yang","year":"2014","journal-title":"Gastroenterology"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2542-9930.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T23:02:48Z","timestamp":1745622168000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2542-9930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":130,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,4,25]]},"published-print":{"date-parts":[[2025,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2542-9930","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}